头孢吡肟与氨曲南治疗急性泌尿系感染的疗效及成本评价  

Therapeutic effects and cost-profit analysis between Cefepime and Aztreonam for acute urinary infections

作　　者：方宝霞[1] 陈富超[1] 林洁[1] 于琳[1] 

机构地区：[1]湖北医药学院附属东风医院,湖北十堰442008

出　　处：《西部医学》2011年第11期2208-2209,共2页Medical Journal of West China

摘　　要：目的观察头孢吡肟与氨曲南治疗急性泌尿系统感染的临床疗效,并进行药物经济学评价。方法 78例泌尿系统感染患者随机分成两组,分别给予头孢吡肟(A组)、氨曲南(B组)治疗7d,分析每组的疗效并运用最小成本分析法进行经济学评价。结果 A、B组总有效率分别为92.50%与94.74%(P>0.05),A、B组成本分别为328.5元与604.8元,成本-效果比分别为3.55与6.38。结论头孢吡肟与氨曲南治疗急性泌尿系统感染疗效确切,头孢吡肟更经济。Objective To evaluate the therapeutic efects and cost-profit analysis between cefepime and aztreonam for acute urinary infections.Methods A total of 78 acute urinary infections patients were randomized to Group A（Cefepime） and Group B（Aztreonam） with a course of treatment at 7 days for each Group.The cost-minimization analysis was conducted for the evaluation of the two schemes.Results The effective rate between cefepime and aztreonam were 92.50% and 94v74%（P〉0.05）.The total costs of two schernes were 328.5 and 604.8 yuan,the cost-effectiveness ratios were 3.55 and 6.38.Conclusion The results suggest that cefepime and aztreonam is highly efective in treating acute urinary infections.Cefepime was proved to be the best therapeutic regime.

关 键 词：急性泌尿系统感染 头孢吡肟 氨曲南 成本-效果分析 

分 类 号：R691.3[医药卫生—泌尿科学]